Browsing by Subject "Acquired Immunodeficiency Syndrome"

Now showing 1 - 6 of 6
  • Thumbnail Image
    Item
    Academic Model for Prevention and Treatment of HIV/AIDS (AMPATH)
    (Association of Kenya Physicians, 2007) Kimaiyo, S. N.; Association of Kenya Physicians Scientific Conference (11th : Mar. 2007 : Eldoret, Kenya)
    AMPATH HIV Care: Now caring for over 48 004 active patients (40 500 Adults and 7,504children) as of 31stMay 2007 with 2,905 new patients in April. 21,397 patients are on ARVs and 583 on TpMTCT
  • Thumbnail Image
    Item
    Counterpoint: Cord blood stem cell therapy for acquired immune deficiency syndrome
    (Mary Ann Liebert, 2001-01) Alkhatib, Ghalib; Microbiology and Immunology, School of Medicine
    Comment on Cord blood stem cell therapy for acquired immune deficiency syndrome. [Stem Cells Dev. 2009]
  • Thumbnail Image
    Item
    Endemic mycosis
    (Springer Nature, 2005) Hage, Chadi A.; Knox, Kenneth S.; Sarosi, George A.; Department of Medicine, Indiana University School of Medicine
  • Thumbnail Image
    Item
    A high-affinity inhibitor of human CD59 enhances complement-mediated virolysis of HIV-1: implications for treatment of HIV-1/AIDS
    (The American Association of Immunologists, 2010-01-01) Hu, Weiguo; Yu, Qigui; Hu, Ningjie; Byrd, Daniel; Amet, Tohti; Shikuma, Cecilia; Shiramiz, Bruce; Halperin, Jose A.; Qin, Xuebin; Department of Microbiology and Immunology, IU School of Medicine
    Many pathogenic enveloped viruses, including HIV-1, escape complement-mediated virolysis by incorporating host cell regulators of complement activation into their own viral envelope. The presence of complement regulators including CD59 on the external surface of the viral envelope confers resistance to complement-mediated virolysis, which may explain why human pathogenic viruses such as HIV-1 are not neutralized by complement in human fluids, even in the presence of high Ab titers against the viral surface proteins. In this study, we report the development of a recombinant form of the fourth domain of the bacterial toxin intermedilysin (the recombinant domain 4 of intermedilysin [rILYd4]), a 114 aa protein that inhibits human CD59 function with high affinity and specificity. In the presence of rILYd4, HIV-1 virions derived from either cell lines or peripheral blood mononuclear cells of HIV-1-infected patients became highly sensitive to complement-mediated lysis activated by either anti-HIV-1 gp120 Abs or by viral infection-induced Abs present in the plasma of HIV-1-infected individuals. We also demonstrated that rILYd4 together with serum or plasma from HIV-1-infected patients as a source of anti-HIV-1 Abs and complement did not mediate complement-mediated lysis of either erythrocytes or peripheral blood mononuclear cells. These results indicate that rILYd4 may represent a novel therapeutic agent against HIV-1/AIDS.
  • Thumbnail Image
    Item
    HIV Induced Disorders of Electrolyte Balance
    (Association of Kenya Physicians, 2007) Abdullah, Mohamed S.; Association of Kenya Physicians Scientific Conference (11th : Mar. 2007 : Eldoret, Kenya)
    Hyponatremia usually results from retention of water due to impairment of free water excretion or sodium loss exceeding that of water loss e.g thiazide-induced hyponatremia, or from multiple factors, as is seen in HIV/AIDS.
  • Thumbnail Image
    Item